Project Grant K23HL171871
Award Date
1/15/25
Completion Date
12/31/29
Dollars Obligated
$196K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $539,218 project grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania to develop novel prediction models and identify subphenotypes for interstitial lung disease (ILD) in patients with myositis. The primary goals are to: 1) Utilize a large, diverse patient cohort to create a prediction model for progression-free survival in myositis-ILD using known and novel biomarkers, and 2)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $771,751 to The University of Texas Southwestern Medical Center to conduct research on the prognostic and predictive impact of telomere length in fibrotic interstitial lung disease (ILD). The key objectives are to: 1) quantify the age-adjusted telomere length threshold that informs differential progression and mortality risk in ILD...
This $189,332 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, aims to develop a remote patient monitoring (RPM)-informed clinical decision support (CDS) tool for managing patients with interstitial lung disease (ILD). The key objectives are to: 1) identify provider and health system barriers to adopting an RPM-informed CDS tool, 2) evaluate the performance of ILD risk classification...
This $100,000 Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) aims to investigate the role of immune and inflammatory cells in driving the pathological fibrosis seen in systemic sclerosis-associated interstitial lung disease (SSc-ILD). The University of Pittsburgh will refine explant culture methodologies to examine the effect of key cytokines, such as TGF-beta, PDGF, IL-6, and IL-13, on healthy control and SSc-ILD lung cells....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $313,632 to National Jewish Health to support a 5-year research project. The project aims to determine if interleukin-6 (IL-6) signaling drives fibroblast apoptosis resistance through increased expression of the anti-apoptotic protein BCL-2, and whether targeting this IL-6-BCL-2 axis can reverse progressive pulmonary fibrosis. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $604,115 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a longitudinal observational study. The study aims to determine if advanced PET and MRI imaging techniques can predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis...
This $844,386 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports the "Integrative Genomics of Childhood Interstitial Lung Disease" research project at Boston Children's Hospital. The key objectives are to: Define patient clusters with similar molecular profiles from 300 childhood interstitial and diffuse lung disease (CHILD) lung biopsy samples, develop a CHILD molecular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to better understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis-associated interstitial lung disease (SSc-ILD). The total funding amount is $110,959, with the award period running from August 1, 2024 to July 31, 2026. The research aims to define the regulatory...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $805,845 to the Proteogenomics Research Institute for Systems Medicine in La Jolla, CA to develop novel lung-targeted therapies for treating lung fibrosis. The key products and services to be delivered under this four-year grant include: 1) generating and testing in vitro the efficacy of therapeutics that target caveolae in...
This $389,754 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is supporting research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The research aims to evaluate the peptide's efficacy in reducing fibrosis in a murine model, as well as conduct pilot toxicity, pharmacokinetic, and biodistribution analyses....